← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Chromologic, Llc
Monrovia, CA
$31,002,520
Total funding
24
Grants
Funding over time
peak $5.7M · FY2011–25$10M$7.5M$5M$2.5M$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$30,696,051 · 23
CDC$306,469 · 1
By mechanism
N01$15,483,638 · 3
R44$4,603,284 · 2
N43$3,524,446 · 8
R42$2,716,925 · 2
R43$1,572,413 · 5
N44$1,498,121 · 1
Investigators at Chromologic, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
Not enough data
Largest grants
POINT-OF-CARE BIOLOGICAL ASSAY FOR DETERMINING TISSUE-SPECIFIC ABSORBED IONIZING RADIATION DOSE (BIODOSIMETER) AFTER RADIOLOGICAL AND NUCLEAR EVENTS.$2,431,186
N01 · FY2018 · AI
Development of Radiation/Nuclear Medical Countermeasures (MCMs) and Biodosimetry Devices$2,280,705
N01 · FY2024 · AI
POINT-OF-CARE BIOLOGICAL ASSAY FOR DETERMINING TISSUE-SPECIFIC ABSORBED IONIZING RADIATION DOSE (BIODOSIMETER) AFTER RADIOLOGICAL AND NUCLEAR EVENTS.$2,033,090
N01 · FY2019 · AI
POINT-OF-CARE BIOLOGICAL ASSAY FOR DETERMINING TISSUE-SPECIFIC ABSORBED IONIZING RADIATION DOSE (BIODOSIMETER) AFTER RADIOLOGICAL AND NUCLEAR EVENTS.$1,822,601
N01 · FY2017 · AI
MIDOS: A MICRORNA BIODOSIMETER$1,599,007
N01 · FY2023 · AI
COVID-19 Supplemental work: POINT-OF-CARE BIOLOGICAL ASSAY FOR DETERMINING TISSUE-SPECIFIC ABSORBED IONIZING RADIATION DOSE (BIODOSIMETER).$1,499,993
N01 · FY2020 · AI
CRISPR-based Assay for Portable Tropical Infection Diagnosis$1,499,763
N43 · FY2025 · AI
Mobile Health Point-of-Care Diagnostics for Malaria$1,498,121
N44 · FY2021 · AI
Development of second-generation probiotics as radiation mitigators$1,486,299
N01 · FY2022 · AI
Mitigation of Ionizing Irradiation-Induced Intestinal Damage by Second-Generation Probiotic LR-IFN-β$1,015,000
R42 · FY2025 · AI
MicroRNA-based Radiation Biodosimeter (MiRAD) Phase II$1,000,000
R44 · FY2019 · AI
MicroRNA-based Radiation Biodosimeter (MiRAD) Phase II$999,895
R44 · FY2020 · AI
MicroRNA-based Radiation Biodosimeter (MiRAD) Phase II$999,884
R44 · FY2018 · AI
Development of Radiation/Nuclear Medical Countermeasures (MCMs) and Biodosimetry Devices$999,637
N01 · FY2025 · AI
NGS based metagenomic screening of ocular infections$898,365
R42 · FY2025 · EY
Development of second-generation probiotics as radiation mitigators$832,579
N01 · FY2023 · AI
Ocular Flare Meter (OFAM) Development Phase II$830,773
R44 · FY2016 · EY
NGS based metagenomic screening of ocular infections$803,560
R42 · FY2024 · EY
Ocular Flare Meter (OFAM) Development Phase II$772,732
R44 · FY2017 · EY
Validation of a microRNA panel to pre-symptomatically predict the risk of radiation-induced fibrosis$533,384
U01 · FY2025 · AI